Insight Molecular Diagnostics Inc. Net Income (Loss) Available to Common Stockholders, Basic
Insight Molecular Diagnostics Inc. (IMDX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$50.22 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-26
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$22.95M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$10.85M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$9.74M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$6.67M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$50.22M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$60.93M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$28.72M.
- Insight Molecular Diagnostics Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$73.42M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$22.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$33.81M derived: sum of 2 quarters · filed 2026-03-26 | -$43.55M derived: sum of 3 quarters · filed 2026-03-26 | -$50.22M 10-K · filed 2026-03-26 | |
| 2025-09-30 | -$10.85M 10-Q · filed 2025-11-10 | -$20.60M derived: sum of 2 quarters · filed 2025-11-10 | -$27.27M 10-Q · filed 2025-11-10 | -$60.78M derived: sum of 4 quarters · filed 2026-03-26 | |
| 2025-06-30 | -$9.74M 10-Q · filed 2025-08-11 | -$16.41M 10-Q · filed 2025-08-11 | -$49.92M derived: sum of 3 quarters · filed 2026-03-26 | -$63.42M derived: sum of 4 quarters · filed 2026-03-26 | |
| 2025-03-31 | -$6.67M 10-Q · filed 2025-05-12 | -$40.18M derived: sum of 2 quarters · filed 2026-03-26 | -$53.67M derived: sum of 3 quarters · filed 2026-03-26 | -$58.26M derived: sum of 4 quarters · filed 2026-03-26 | |
| 2024-12-31 | -$33.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$47.00M derived: sum of 2 quarters · filed 2026-03-26 | -$51.59M derived: sum of 3 quarters · filed 2026-03-26 | -$60.93M 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$13.49M 10-Q · filed 2025-11-10 | -$18.08M derived: sum of 2 quarters · filed 2025-11-10 | -$27.41M 10-Q · filed 2025-11-10 | -$43.61M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$4.59M 10-Q · filed 2025-08-11 | -$13.92M 10-Q · filed 2025-08-11 | -$30.12M derived: sum of 3 quarters · filed 2025-08-11 | -$36.80M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$9.34M 10-Q · filed 2025-05-12 | -$9.34K 10-Q · filed 2024-05-15 | -$25.53M derived: sum of 2 quarters · filed 2025-05-12 | -$32.22M derived: sum of 3 quarters · filed 2025-05-12 | -$40.86M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$22.88M derived: sum of 2 quarters · filed 2025-03-24 | -$31.53M derived: sum of 3 quarters · filed 2025-03-24 | -$28.72M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$6.69M 10-Q · filed 2024-11-12 | -$15.33M derived: sum of 2 quarters · filed 2024-11-12 | -$12.53M 10-Q · filed 2024-11-12 | -$60.53M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$8.64M 10-Q · filed 2024-08-08 | -$5.84M 10-Q · filed 2024-08-08 | -$53.85M derived: sum of 3 quarters · filed 2024-08-08 | -$63.47M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.40K 10-Q · filed 2024-05-15 | $2.40M 10-Q · filed 2023-05-15 | -$45.20M derived: sum of 2 quarters · filed 2024-05-15 | -$54.83M derived: sum of 3 quarters · filed 2024-05-15 | -$63.20M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$45.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$54.83M derived: sum of 2 quarters · filed 2024-04-16 | -$63.20M derived: sum of 3 quarters · filed 2024-04-16 | -$73.42M 10-K · filed 2024-04-16 | |
| 2022-09-30 | -$9.63M 10-Q · filed 2023-11-09 | -$9.55M 10-Q · filed 2022-11-10 | -$18.00M derived: sum of 2 quarters · filed 2023-11-09 | -$28.22M 10-Q · filed 2023-11-09 | -$64.17M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$8.37M 10-Q · filed 2023-08-10 | -$18.66M 10-Q · filed 2023-08-10 | -$54.55M derived: sum of 3 quarters · filed 2023-08-10 | -$68.35M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$10.29M 10-Q · filed 2023-05-15 | -$46.18M derived: sum of 2 quarters · filed 2023-05-15 | -$59.98M derived: sum of 3 quarters · filed 2023-05-15 | -$70.47M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$35.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-12 | -$49.69M derived: sum of 2 quarters · filed 2023-04-12 | -$60.18M derived: sum of 3 quarters · filed 2023-04-12 | -$64.10M 10-K · filed 2023-04-12 | |
| 2021-09-30 | -$13.80M 10-Q · filed 2022-11-10 | -$24.29M derived: sum of 2 quarters · filed 2022-11-10 | -$28.21M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$10.49M 10-Q · filed 2022-08-12 | -$14.41M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |